Evgen Pharma Share Discussion Threads

[amaretto1] 28/1/2022 20:10

He's had an agenda since he started posting ... Never said one positive thing about this company... just trying to sow doubt !

[btgman] 28/1/2022 20:01

Kingalf

What on earth are you going on about below is a quote taken from HMRC




Companies that can use the scheme
Your company can use the scheme if it:

has a permanent establishment in the UK
is not trading on a recognised stock exchange at the time of the share issue and does not plan to do so
does not control another company other than qualifying subsidiaries
is not controlled by another company, or does not have more than 50% of its shares owned by another company
does not expect to close after completing a project or series of projects

Mr Kight has clearly been buying on the open market building an incredible stake and as Evgen moves to next stage of trials will see a very handsome reward.

Evgen is valued at not much over cash balance any sniff of partner development agreement will see this multiply several times over.

All you need with this is a little patience something very few have sadly and to their cost.

AIMHO
GLA
BTG

[lovewinshatelosses] 28/1/2022 11:53

Well, I enjoyed the interview anyway! No idea where the share price will be at the end of this year, but one way or the other 2022 is going to see something happen here. GLA.

[kingalf] 27/1/2022 13:10

Kight is done with his buying, got to around the maximum permissible amount (£2 million) he can use within his tax scheme, The Directors could always step up to the mark, but I won't be holding my breath.

[clocktower] 27/1/2022 12:45

The investor might well be thinking they can buy another 11% for a lot less than they paid to acquire the current 11% holding, as long as they wait a little longer for the share price to sink even lower.

[kingalf] 27/1/2022 07:32

These interviews are so scripted, the 2 questions she should have asked were, if you feel so confident, why haven't you invested directly yourself and secondly, any views on this new investor who has built a 11% plus holding in your company.

[mrwizard1] 26/1/2022 22:01

Same old talk. I agree with Kingalf on LSE ""Ramping up staff has produced huge benefits"
I take it that he means staff pockets, it certainly hasn't benefited the shareholders.
It's like a season finali of a never ending series, gives you enough to come back and watch the next series, but we all secretly know it will be same old story line going forward.""

Shareholder value will not increase with academic licenses or regulatory approvals or clinical trials scheduled at end of the year. Company needs a validation Big Pharma deal.

[on target] 26/1/2022 18:28

New Huw interview:



Lots going on this year and sounds like plenty of newsflow to come over the coming months. Might actually see the share price start to rise at some point!

[kingalf] 24/1/2022 19:55

If the share price keeps dropping, it will be more cost effective for Juvenescence to buyout the company then pay any future royalties.

[on target] 20/1/2022 13:40

There's the sub-5p.
150k+ on offer Mr Kight.

[lovewinshatelosses] 18/1/2022 07:30

Another positive building block. It wont set the share price alight I guess, but I certainly cannot see anything negative in it either, so yesterday's tree shake is unlikely to be the result of any leaks.
All that said, this share moves in totally mystifying ways, so I will just sit back and continue to watch how things unfold....

[moneymunch] 18/1/2022 07:01

RNS Number : 7343Y
Evgen Pharma PLC
18 January 2022






Evgen Pharma plc

("Evgen" or "the Company")



Option over new sulforaphane analogues



Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases, announces a Memorandum of Understanding with the University of Seville ('US'), Consejo Superior de Investigaciones Científicas ('CSIC') and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville, for second generation sulforaphane analogues.



Under the agreement Evgen has signed an exclusive option to license new, novel sulforaphane analogues synthesised by these Spanish institutions, subject to a fixed evaluation period. These analogues have the potential for differentiation from SFX-01 in terms of product formulation. They may also have the potential for differential activity against targets that Evgen is pursuing such as STAT3, SHP2 and Nrf2. As such, they could constitute follow-on and/or alternative products which would expand Evgen's development and partnering opportunities.



If the option is exercised it would expand substantially Evgen's preclinical pipeline of sulforaphane analogues. Analogues from an existing license from US and CSIC are currently undergoing further screening against relevant targets. The current option will be exercised should the Company's technical evaluation be positive.



Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted that we are extending our collaboration with the CSIC and University of Seville, and the opportunity this gives us to broaden our sulforaphane-based drug pipeline. If differentiation is demonstrated in the laboratory, we then have considerable potential to target diseases where one of the key molecular targets for sulforaphane is more relevant than others, enhancing our pipeline substantially."

[markth126] 17/1/2022 18:43

Interested to hear what thoughts people have around me kight continually increasing stake up to 11% + , seems pretty confident though.

[amaretto1] 17/1/2022 16:40

Course you are !!! Dilusional has ever

[clocktower] 17/1/2022 16:39

LOL - well underwater are you. As for why I am here, is it not clear to you that I am waiting until the price hits the target that I am willing to buy a few at, as a high risk punt.

DYOR

[clocktower] 17/1/2022 16:24

Correction On Target - I would suggest to you that is wishful thinking and that it is more likely called betting.

Furthermore, the pipeline shows that the other products are still way behind and will no-doubt need a whole pile of the cash funding the company sits on and that is being swallowed up all the time.

Good luck but you might be better paying for your funeral in advance before that ticket rises, rather than dreaming these tickets will be worth the wait.

Good Luck

[markth126] 17/1/2022 16:24

Reckon kight is buying again with a late frenzy just now!!

[markth126] 17/1/2022 16:23

I personally like to drip amounts in at varying levels and just feel that this level isGood value today given what we know, and news can catch people out any day with these.

[clocktower] 17/1/2022 16:13

Take a look at the pipeline and see how far they yet have to travel, and why buy a ticket before they have even reached the third station?



The websites done no favours imo and what a daft way to spend the companies cash, when there is so much left to do.

[kingalf] 17/1/2022 16:12

Seems to have hit a support line stretching back to March 2020.
Clearly the seller wasn't happy that they've blown a load of cash revamping their website.

[clocktower] 17/1/2022 15:58

You'll get many more chances to buy under 5p imo markth126. :-)

[markth126] 17/1/2022 15:36

Yeah, can't buy a grands worth now!!

[on target] 17/1/2022 15:29

Nice one, can't buy a thing now - what a surprise.